Retrospective cohort study of neoadjuvant chemotherapy followed by tailored surgery in locally advanced sphincter-threatening vulval cancer: an alternative to exenteration?

Objective: To determine the feasibility and overall survival (OS) outcome of utilizing neoadjuvant chemotherapy (NACT) followed by wide local excision (WLE) in women with sphincter-threatening locally advanced squamous cell carcinoma (SCC) of the vulva. Methods: The electronic chemotherapy prescribing system was used to iden-tify patients from the West of Scotland Cancer Network (WoSCAN) who received NACT over a 5 year period, January 2012 to December 2016 inclusive. Baseline characteristics and treatment details were collected. Association of treatment type and other variables with OS were analysed using Cox proportional hazards model. Results: 57 patients with newly diagnosed SCC of the vulva were identified; recurrences were excluded. 25 patients proceeded to WLE following NACT. No permanent stomas were required. 4% of patients had a complete response with NACT alone, not undergoing surgery, and remained disease free at the study end. OS was 39.3 months (95%Confidence Interval (CI) 32.5 – Not reached (NR)) for the entire cohort and 40.1 months (95% CI 39.3 – NR) in the surgical group following median follow up of 27 months. Local recurrence was the predominant cause of failure. Conclusions: NACT followed by WLE is effective in a subgroup of patients with locally advanced vulval cancer and can minimize the extent of surgery necessary, but close monitoring is required to identify and manage relapse early.

Vulval cancer; Neoadjuvant chemotherapy; Surgery; Radiotherapy; Wide local excision; Real-world

[1] Cancer Research UK. Vulval cancer. 2019. Available at: http s://www.cancerresearchuk.org/about-cancer/vulval-cancer (Accessed: 16 June 2020).

[2] Kang Y, Smith M, Barlow E, Coffey K, Hacker N, Canfell K. Vulvar cancer in high-income countries: Increasing burden of disease. International Journal of Cancer. 2017; 141: 2174–2186.

[3] Dellinger TH, Hakim AA, Lee SJ, Wakabayashi MT, Morgan RJ, Han ES. Surgical Management of Vulvar Cancer. Journal of the National Comprehensive Cancer Network. 2017; 15: 121–128.

[4] te Grootenhuis NC, van der Zee AGJ, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) i. Gynecologic Oncology. 2016; 140: 8–14.

[5] Boronow RC. Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: Rationale and results. Cancer. 1982; 49: 1085–1091.

[6] Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. International Journal of Radiation Oncology*Biology*Physics. 1998; 42: 79–85.

[7] Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. International Journal of Radiation Oncology*Biology*Physics. 2000; 48: 1007–1013.

[8] Durrant KR, Mangioni C, Lacave AJ, George M, van der Burg MEL, Guthrie D, et al. Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC gynaecological cancer cooperative group (GCCG). Gynecologic Oncology. 1990; 37: 359–362.

[9] Benedetti-Panici P, Greggi S, Scambia G, Salerno G, Mancuso S. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecologic Oncology. 1993; 50: 49–53.

[10] Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecologic Oncology. 2001; 81: 348–354.

[11] Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecologic Oncology. 2006; 100: 53–57.

[12] Domingues AP, Mota F, Durão M, Frutuoso C, Amaral N, de Oliveira CF. Neoadjuvant chemotherapy in advanced vulvar cancer. International Journal of Gynecological Cancer. 2010; 20: 294–298.

[13] Aragona AM, Cuneo N, Soderini AH, Alcoba E, Greco A, Reyes C, et al. Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study. International Journal of Gynecological Cancer. 2012; 22: 1258–1263.

[14] Han SN, Vergote I, Amant F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. International Journal of Gynecological Cancer. 2012; 22: 865–868.

[15] Raspagliesi F, Zanaboni F, Martinelli F, Scasso S, Laufer J, Ditto A. Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. Journal of Gynecologic Oncology. 2014; 25: 22–29.

[16] Niu Y, Yin R, Wang D, Li Q, Gao X, Huang M. Clinical analysis of neoadjuvant chemotherapy in patients with advanced vulvar cancer: a STROBE-compliant article. Medicine. 2018; 97: e11786.

[17] Baillie K, Mueller T, Pan J, Laskey J, Bennie M, Crearie C, et al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety. 2020; 29: 653–663.

[18] Information Services Division (ISD) Scotland. ACaDMe. 2018. Available at: http://www.isdscotland.org/Products-and-Service s/ACaDMe/ (Accessed: 2 February 2018).

[19] The R Foundation. The R Project for Statistical Computing. 2017. Available at: https://www.r-project.org/ (Accessed: 2 February 2018).

[20] Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer. 2012; 107: 695–699.

[21] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987; 40: 373–383.

[22] Scottish Government. The Scottish Index of Multiple Deprivation (SIMD). 2012. Available at: www.gov.scot/Topics/Statistics/SIM D (Accessed: 2 February 2018).

[23] Marco A, Luca B, Andrea AL, Francesca V, Serena N, Tommaso G, et al. Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience. Tumori Journal. 2021. (in press)

[24] Hinten F, van den Einden LCG, Cissen M, IntHout J, Massuger LFAG, de Hullu JA. Clitoral involvement of squamous cell carcinoma of the vulva: localization with the worst prognosis. European Journal of Surgical Oncology. 2015; 41: 592–598.

[25] Hinten F, Molijn A, Eckhardt L, Massuger LFAG, Quint W, Bult P, et al. Vulvar cancer: Two pathways with different localization and prognosis. Gynecologic Oncology. 2018; 149: 310–317.

[26] Yap ML, Allo G, Cuartero J, Pintilie M, Kamel-Reid S, Murphy J, et al. Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. Clinical Oncology. 2018; 30: 254–261.

[27] Shylasree TS, Bryant A, Howells RE. Chemoradiation for advanced primary vulval cancer. The Cochrane Database of Systematic Reviews. 2011; 2011: CD003752.

[28] Forner DM, Mallmann P. Neoadjuvant and definitive chemotherapy or chemoradiation for stage III and IV vulvar cancer: a pooled Reanalysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017; 212: 115–118.

[29] Micheletti L, Preti M, Cintolesi V, Corvetto E, Privitera S, Palmese E, et al. Prognostic impact of reduced tumor-free margin distance on long-term survival in FIGO stage IB/II vulvar squamous cell carcinoma. Journal of Gynecologic Oncology. 2018; 29: e61.

[30] Rao YJ, Chin R, Hui C, Mutch DG, Powell MA, Schwarz JK, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: a review of the National Cancer Database. Gynecologic Oncology. 2017; 146: 572–579.

[31] Richman AH, Vargo JA, Ling DC, Sukumvanich P, Berger JL, Boisen MM, et al. Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer - does it increase response rate? Gynecologic Oncology. 2020; 159: 657–662.

[32] Rango: A study to collect accessible information about patients with rare neoplasms of gynaecological origin in the UK. International Journal of Gynecological Cancer. Conference: 21st European Congress on Gynaecological Oncology, ESGO 2019. Greece. BMJ Publishing Group. 2019.

[33] Perrone AM, Galuppi A, Pirovano C, Borghese G, Covarelli P, De Terlizzi F, et al. Palliative Electrochemotherapy in Vulvar Carcinoma: Preliminary Results of the ELECHTRA (Electrochemotherapy Vulvar Cancer) Multicenter Study. Cancers. 2019; 11: 657.

[34] Perrone AM, Galuppi A, Borghese G, Corti B, Ferioli M, Della Gatta AN, et al. Electrochemotherapy pretreatment in primary squamous vulvar cancer. our preliminary experience. Journal of Surgical Oncology. 2018; 117: 1813–1817.

[35] Naumann RW, Hollebecque A, Meyer T, Devlin M, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results from the Phase i/II CheckMate 358 Trial. Journal of Clinical Oncology. 2019; 37: 2825–2834.

[36] Klavans MR, Erickson SH, Modesitt SC. Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care? Gynecologic Oncology Reports. 2020; 34: 100631.